July 25, 2013

Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013

- Conference call with investment community to follow -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter of 2013, on Wednesday, August 7, 2013 before the market opens. The announcement will be followed by a conference call with the investment community, also on Wednesday, August 7, 2013, at 8:30 a.m. EDT, to provide a business update and discuss the Company's financial and operational results.

Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until August 21, 2013. The conference call can be accessed as follows:

CONFERENCE CALL INFORMATION TO PARTICIPATE LIVE:		**TO LISTEN TO A REPLAY:**	
		Available until:	August 21, 2013
Date:	August 7, 2013	Toll-free (U.S.) Dial in #:	(877) 660-6853
Time:	8:30 a.m. EDT	International Dial in #:	(201) 612-7415
Toll-free (U.S.) Dial in #:	(877) 407-8031	Replay passcode:	
International Dial in #:	(201) 689-8031	Account #:	268
		Conference ID #:	418275

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScan™ – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Executive VP & CFO
or
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200

Source: Navidea Biopharmaceuticals Inc.